University of Washington and the Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue, Seattle, WA, 98109, USA.
Best Pract Res Clin Haematol. 2021 Dec;34(4):101320. doi: 10.1016/j.beha.2021.101320. Epub 2021 Oct 22.
Outcomes with conventional chemotherapy for older patients with acute myeloid leukemia (AML) remain disappointing, with few cures. For younger patients with AML, allogeneic hematopoietic cell transplantation (HCT) offers the best chance for cure, but this strategy is seldomly used for older patients. With recently improved methodologies, transplantation has become increasingly safe, suggesting that its use in older patients be reconsidered. This report will address four issues: the current frequency of transplantation for AML according to patient age; the impact of patient age on transplant outcomes; the comparative outcomes of transplantation versus chemotherapy for older patients with AML; and possible methods to improve the outcome of allogeneic HCT in older patients with AML.
对于老年急性髓系白血病（AML）患者，传统化疗的结果仍然令人失望，治愈的病例很少。对于年轻的 AML 患者，异基因造血细胞移植（HCT）是治愈的最佳机会，但这种策略很少用于老年患者。随着最近方法的改进，移植变得越来越安全，这表明应重新考虑在老年患者中使用该方法。本报告将讨论四个问题：根据患者年龄，AML 患者接受移植的当前频率；患者年龄对移植结果的影响；AML 老年患者移植与化疗的比较结果；以及改善老年 AML 患者异基因 HCT 结果的可能方法。
